FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255368440> ?p ?o ?g. }

• W4255368440 endingPage "162" @default.
• W4255368440 startingPage "162" @default.
• W4255368440 abstract "162 Background: Our recent data have shown that carboplatin AUC5 on d1 plus docetaxel at a dose of 35 mg/m2 iv on d1, 8, 15 every 4 weeks (q4w) is an effective salvage therapy in mDRPC. Patients (pts) who have progressive disease during DC treatment survive only ~7 months and many are symptomatic. We have demonstrated that high free testosterone (FT) serum levels during DC treatment have a negative prognostic value for PSA response and overall survival in these pts. In this study the impact of abiraterone treatment and other subsequent salvage regimens after DC failure was analyzed. Methods: DC failure was defined as disease progression during DC treatment according to the Prostate Cancer Working Group (PCWG2 2007) criteria. Since February 2005, 74 consecutive DRPC pts were treated with at least 2 cycles DC until disease progression. At the time of the current analysis 67 pts have progressed and 41 pts received one or more subsequent therapies (1-3). Results: Overall survival (OS) of all 67 pts who have progressed during DC treatment was 7.1 months (CI 95% 1.8, 12.3). 41 pts received subsequent salvage therapies including mitoxantrone-prednisone-etoposide (MPE) (n=10), cabazitaxel (n=10), docetaxel-oxaliplatin (n=8), abiraterone (n=15) and doxorubicin-ketokonazol (n=5). OS of these 41 pts was 14.6 months (CI 95% 11.0, 18.3).In pts receiving abiraterone as salvage treatment, OS after DC was 21.8 months (CI 95% 7.2, 36.5) versus 11.9 months (CI 95% 9.0, 14.8) in pts receiving other regimens (HR 0.302, CI 95% 0.11, 0.8; p=0.016). Responses of prostate-specific antigen (PSAR; ≥30% and ≥50%) were only observed in pts receiving abiraterone (8/15, 53.3% and 4/15, 26.7%, respectively). Conclusions: Our data demonstrate for the first time that testosterone is an important prognostic factor for PSA response and OS in mDRPC patients receiving DC chemotherapy and that targeting testosterone after DC failure prolongs post-DC survival." @default.
• W4255368440 created "2022-05-12" @default.
• W4255368440 creator A5001987856 @default.
• W4255368440 creator A5011083669 @default.
• W4255368440 creator A5012177478 @default.
• W4255368440 creator A5013231760 @default.
• W4255368440 creator A5081076272 @default.
• W4255368440 date "2013-02-20" @default.
• W4255368440 modified "2023-09-30" @default.
• W4255368440 title "Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC)." @default.
• W4255368440 doi "https://doi.org/10.1200/jco.2013.31.6_suppl.162" @default.
• W4255368440 hasPublicationYear "2013" @default.
• W4255368440 type Work @default.
• W4255368440 citedByCount "0" @default.
• W4255368440 crossrefType "journal-article" @default.
• W4255368440 hasAuthorship W4255368440A5001987856 @default.
• W4255368440 hasAuthorship W4255368440A5011083669 @default.
• W4255368440 hasAuthorship W4255368440A5012177478 @default.
• W4255368440 hasAuthorship W4255368440A5013231760 @default.
• W4255368440 hasAuthorship W4255368440A5081076272 @default.
• W4255368440 hasConcept C121608353 @default.
• W4255368440 hasConcept C126322002 @default.
• W4255368440 hasConcept C126894567 @default.
• W4255368440 hasConcept C141071460 @default.
• W4255368440 hasConcept C143998085 @default.
• W4255368440 hasConcept C2776694085 @default.
• W4255368440 hasConcept C2777511904 @default.
• W4255368440 hasConcept C2777899217 @default.
• W4255368440 hasConcept C2778239845 @default.
• W4255368440 hasConcept C2778822529 @default.
• W4255368440 hasConcept C2778971682 @default.
• W4255368440 hasConcept C2780192828 @default.
• W4255368440 hasConcept C2780775027 @default.
• W4255368440 hasConcept C2780923524 @default.
• W4255368440 hasConcept C2781190966 @default.
• W4255368440 hasConcept C2781451048 @default.
• W4255368440 hasConcept C530470458 @default.
• W4255368440 hasConcept C71924100 @default.
• W4255368440 hasConceptScore W4255368440C121608353 @default.
• W4255368440 hasConceptScore W4255368440C126322002 @default.
• W4255368440 hasConceptScore W4255368440C126894567 @default.
• W4255368440 hasConceptScore W4255368440C141071460 @default.
• W4255368440 hasConceptScore W4255368440C143998085 @default.
• W4255368440 hasConceptScore W4255368440C2776694085 @default.
• W4255368440 hasConceptScore W4255368440C2777511904 @default.
• W4255368440 hasConceptScore W4255368440C2777899217 @default.
• W4255368440 hasConceptScore W4255368440C2778239845 @default.
• W4255368440 hasConceptScore W4255368440C2778822529 @default.
• W4255368440 hasConceptScore W4255368440C2778971682 @default.
• W4255368440 hasConceptScore W4255368440C2780192828 @default.
• W4255368440 hasConceptScore W4255368440C2780775027 @default.
• W4255368440 hasConceptScore W4255368440C2780923524 @default.
• W4255368440 hasConceptScore W4255368440C2781190966 @default.
• W4255368440 hasConceptScore W4255368440C2781451048 @default.
• W4255368440 hasConceptScore W4255368440C530470458 @default.
• W4255368440 hasConceptScore W4255368440C71924100 @default.
• W4255368440 hasIssue "6_suppl" @default.
• W4255368440 hasLocation W42553684401 @default.
• W4255368440 hasOpenAccess W4255368440 @default.
• W4255368440 hasPrimaryLocation W42553684401 @default.
• W4255368440 hasRelatedWork W1571712 @default.
• W4255368440 hasRelatedWork W1852032 @default.
• W4255368440 hasRelatedWork W2073444 @default.
• W4255368440 hasRelatedWork W2544042 @default.
• W4255368440 hasRelatedWork W370487 @default.
• W4255368440 hasRelatedWork W6339096 @default.
• W4255368440 hasRelatedWork W8234051 @default.
• W4255368440 hasRelatedWork W8438325 @default.
• W4255368440 hasRelatedWork W895291 @default.
• W4255368440 hasRelatedWork W9962084 @default.
• W4255368440 hasVolume "31" @default.
• W4255368440 isParatext "false" @default.
• W4255368440 isRetracted "false" @default.
• W4255368440 workType "article" @default.